Osimertinib vs Trastuzumab
Osimertinib vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Osimertinib and Trastuzumab.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Osimertinib β 48 hours; Trastuzumab β 28 days.
Chemical Properties
Molecular Formula: Osimertinib β C28H33N7O2.
Molecular Weight: Osimertinib β 499.6050 g/mol.
Type: Osimertinib β Small molecule; Trastuzumab β Antibody.